Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alli Sparks Reevaluation Of OTC Weight-Loss Indication

This article was originally published in The Tan Sheet

Executive Summary

FDA will revisit its thinking about weight loss as an OTC indication as the agency decides whether to allow Xenical to be sold without a prescription
Advertisement

Related Content

FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
FDA Weight-Loss Drug Guidance Touts Lifestyle, Doubts Metabolic Syndrome
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
Ephedra: Experts Speak Out On The Good, The Bad And The Ugly
NDAC’s Wood Departs FDA Committee; Joins Private Investment Firm
Alli Makes Passing Grade On Safety; Advisory Committee Debates Benefit
Alli Makes Passing Grade On Safety; Advisory Committee Debates Benefit
Decreased Supplement Use For Weight Loss Possible OTC Orlistat Benefit
Short-Term Xenical Treatment Benefits “Difficult To Define,” FDA Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS099059

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel